Marked Palliative Benefits Seen With Treatment of Very Advanced Breast Cancer With the Progesterone Receptor Modulator Mifepristone
{{output}}
Background/aim: Treatment of cancers known to be positive for the nuclear progesterone receptor (nPR), e.g., breast, ovarian, and endometrial cancers with PR modulators/antagonists, e.g., mifepristone, have not shown impressive i... ...
